ArticleReproductive biology and endocrinology : RB&E2026
Improvement of fertility in female mice by treatment with novel telomerase-increasing compounds.
Article in Reproductive biology and endocrinology : RB&E, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPharmaceutical approaches to enhance female fertility are especially important for women who delay childbearing and experience age-related fertility decline. Previous studies have highlighted the potential role of telomerase in female reproductive health and fertility. Infertility in fourth-generation telomerase knockout mice, which have critically shortened telomeres, highlights the importance of both telomere length and telomerase in reproductive health. Increasing telomerase levels in the ovary shows promise for enhancing fertility by influencing folliculogenesis, oocyte maturation, and ovulation. AGS compounds, designed by us, transiently increase telomerase reverse transcriptase (TERT) expression and telomerase activity in vitro and in vivo. We therefore examined, for the first time, the effects of AGS compounds on female fertility.
methodsYoung (3–5 months), older (12 months), and TERT-knockout (TERT-KO) female mice were treated with subcutaneous injections of AGS compounds. We then evaluated the effects on ovarian TERT levels, folliculogenesis, ovulation, blood hormone levels, number of embryos and offspring, fertility-related gene expression, and key signaling pathways.
resultsIn both age groups, treatment with AGS increased TERT mRNA levels and telomerase activity in the mouse ovary, leading to faster oocyte maturation and ovulation, as well as higher expression of fertility-related genes. Treatment also elevated plasma levels of progesterone, estrogen, and gonadotropins. Consequently, the number of embryos and offspring increased, with all showing normal development and growth. However, in telomerase-knockout (TERT-KO) mice, AGS treatment did not affect ovarian stage or the expression of certain genes, indicating a TERT-dependent mechanism. Additionally, AGS exert their effects partially through TERT-dependent activation of the Wnt-β-catenin pathway.
conclusionsThese findings demonstrate that transient telomerase activation in the ovary through pharmaceutical compounds may improve female fertility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.